Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials.

about

Time, PASI and DLQI of psoriasis patients who "drop out" of clinical trials on etanercept due to "lack of efficacy" - a pooled analysis from ten clinical trials.

Item

http://www.wikidata.org/entity/Q38644270

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Time, PASI and DLQI of psorias ...... ysis from ten clinical trials.

@en

type

Item

label

Time, PASI and DLQI of psorias ...... ysis from ten clinical trials.

@en

prefLabel

Time, PASI and DLQI of psorias ...... ysis from ten clinical trials.

@en

P1476

Time, Psoriasis Area and Sever ...... alysis from 10 clinical trials

@en

P2093

A Nast

http://www.w3.org/2001/XMLSchema#string

L Aikman

http://www.w3.org/2001/XMLSchema#string

M Dilleen

http://www.w3.org/2001/XMLSchema#string

P Szczypa

http://www.w3.org/2001/XMLSchema#string

W Liyanage

http://www.w3.org/2001/XMLSchema#string

P2860

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Sample size slippages in randomised trials: exclusions and the lost and wayward

Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data.

Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice

Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action.

Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis.

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial).

A randomized trial of etanercept as monotherapy for psoriasis.

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

P304

400-405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1111/BJD.15864

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P50

Corinna Dressler

P577

2018-01-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28771657

http://www.w3.org/2001/XMLSchema#string